Smart combo therapy aims to boost remission in HER2+ breast cancer
NCT ID NCT07565324
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs (PLD, cyclophosphamide, trastuzumab, and pertuzumab) for people with HER2-positive early breast cancer who still have cancer after initial treatment. The goal is to see if this combo can increase the rate of complete remission before surgery while being safer for the heart. The study uses ultrasound and blood DNA tests to guide treatment decisions. About 54 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER 2 POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could routine brain scans catch hidden cancer spread?
- Biosimilar for breast cancer tracked in real-world study
- New drug cocktail aims to wipe out breast cancer before surgery
- New combo therapy aims to boost breast cancer treatment before surgery
- New MRI dye could spot brain tumors sooner in cancer patients
- Can a potato starch supplement ease cancer drug side effects?